Allogene Therapeutics
(NASDAQ) ALLO
Allogene Therapeutics Financials at a Glance
Market Cap
$604.57M
Revenue (TTM)
$0.00
Net Income (TTM)
$190.89M
EPS (TTM)
$-0.87
P/E Ratio
-2.86
Dividend
$0.00
Beta (Volatility)
1.67 (High)
Dividend
$0.00
Beta (Volatility)
1.67 (High)
Price
$2.63
Volume
89,805
Open
$2.48
Price
$2.63
Volume
89,805
Open
$2.48
Previous Close
$2.48
Daily Range
$2.48 - $2.70
52-Week Range
$0.86 - $2.80
Dividend
$0.00
Beta (Volatility)
1.67 (High)
Price
$2.63
Volume
89,805
Open
$2.48
Previous Close
$2.48
Daily Range
$2.48 - $2.70
52-Week Range
$0.86 - $2.80
ALLO News
ALLO: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Allogene Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
152
CEO
David D. Chang, MD, PhD
Website
www.allogene.comHeadquarters
South San Francisco, CA 94080, US
ALLO Financials
Key Financial Metrics (TTM)
Gross Margin
0%
Operating Margin
0%
Net Income Margin
0%
Return on Equity
-53%
Return on Capital
-55%
Return on Assets
-46%
Earnings Yield
-34.97%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$604.57M
Shares Outstanding
243.78M
Volume
89.81K
Short Interest
0.00%
Avg. Volume
5.92M
Financials (TTM)
Gross Profit
$12.36M
Operating Income
$206.93M
EBITDA
$194.57M
Operating Cash Flow
$149.25M
Capital Expenditure
$386.00K
Free Cash Flow
$149.63M
Cash & ST Invst.
$250.21M
Total Debt
$75.05M
Allogene Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
$3.06M
+5.4%
Gross Margin
0.00%
N/A
Market Cap
$604.57M
N/A
Market Cap/Employee
$2.68M
N/A
Employees
226
N/A
Net Income
$38.81M
+35.3%
EBITDA
$39.35M
+30.0%
Quarterly Fundamentals
Net Cash
$166.96M
-17.2%
Accounts Receivable
$1.50M
N/A
Inventory
$0.00
N/A
Long Term Debt
$75.05M
-9.9%
Short Term Debt
$8.21M
+9.3%
Return on Assets
-45.90%
N/A
Return on Invested Capital
-54.60%
N/A
Free Cash Flow
$27.60M
+25.3%
Operating Cash Flow
$27.60M
+24.8%